PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16430309-10 2006 In the case of midazolam, ciclosporin, nifedipine and docetaxel, clearance by individuals with a CYP3A5-expressing genotype did not differ from that for nonexpressors, but in the case of tacrolimus, eight independent studies have demonstrated faster clearance by those carrying one or two CYP3A5*1 alleles. Midazolam 15-24 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 97-103 16243813-0 2005 Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Midazolam 112-121 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 28-34 16243813-1 2005 PURPOSE: To evaluate the effect of naturally occurring variants in genes encoding the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 in patients with cancer receiving midazolam as a phenotyping probe. Midazolam 169-178 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 128-134 15383492-5 2004 Based on this parameter, CYP3A5 was more active than CYP3A4 in catalyzing total midazolam hydroxylation (3-fold) and lidocaine demethylation (1.4-fold). Midazolam 80-89 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 25-31 15900284-9 2005 The carriers of the haplotype CYP3A4*VI had a 1.8-fold higher clearance of midazolam in black subjects (ANOVA on ranks, P = .028) compared with other individuals, and the carriers of the multigene haplotype CYP3A4*VI - CYP3A5*3A had a 1.7-fold higher clearance in the entire population (ANOVA on ranks, P = .012). Midazolam 75-84 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 219-225 14515058-0 2003 Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Midazolam 109-118 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 54-60 15289787-10 2004 However, during cytochrome P450 (CYP) 3A inhibition by itraconazole, individuals carrying the CYP3A5*1 allele were found to be less susceptible to changes in systemic clearance and showed higher 1"-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratios, probably resulting from the relatively CYP3A4-specific inhibition caused by itraconazole. Midazolam 205-214 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 94-100 15499178-6 2004 In addition, the correlation coefficients of CYP3A5 contents with the rates of diltiazem N-demethylation, midazolam 1"-hydroxylation and testosterone 6beta- hydroxylation were higher than those of CYP3A4, although the value of CYP3A5 with the midazolam 4-hydroxylation rate was similar to that of CYP3A4. Midazolam 106-115 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 45-51 15499178-6 2004 In addition, the correlation coefficients of CYP3A5 contents with the rates of diltiazem N-demethylation, midazolam 1"-hydroxylation and testosterone 6beta- hydroxylation were higher than those of CYP3A4, although the value of CYP3A5 with the midazolam 4-hydroxylation rate was similar to that of CYP3A4. Midazolam 243-252 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 45-51 15499178-8 2004 The apparent V(max)/K(m) values for recombinant CYP3A5 indicated the greater contributions to diltiazem N-demethylation and midazolam 1"-hydroxylation as compared with CYP3A4. Midazolam 124-133 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 48-54 15499178-9 2004 These results suggest that polymorphic CYP3A5 contributes markedly to the drug oxidations, particularly diltiazem N-demethylation, midazolam 1"- hydroxylation and testosterone 6beta-hydroxylation by liver microsomes from Japanese subjects. Midazolam 131-140 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 39-45 15289787-0 2004 Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Midazolam 69-78 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 14-20 15289787-1 2004 OBJECTIVE: Our objective was to investigate the effect of the CYP3A5 genotype on the systemic clearance of midazolam in constitutive, inhibited, and induced metabolic conditions. Midazolam 107-116 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 62-68 15289787-8 2004 The 1"-hydroxymidazolam-to-midazolam area under the plasma concentration-time curve ratio was also significantly lower in the CYP3A5*3/*3 group (0.58 +/- 0.35 versus 1.09 +/- 0.37 for the homozygous wild-type group, P =.026). Midazolam 26-36 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 126-132 15179407-7 2004 Mean midazolam clearance was 1.7 times higher in CYP3A5*1/*3 subjects than in CYP3A5*3/*3 subjects (95% confidence interval, 1.15-2.51; P =.01, 2-way ANOVA). Midazolam 5-14 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 49-55 15114431-0 2004 Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Midazolam 20-29 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 45-51 14637191-4 2003 V(max) values for midazolam 1"-hydroxylation and amitriptyline N-demethylation by CYP3A5 were increased about twice by addition of b(5), which was also seen with CYP3A4, although the extent of the effects of b(5) on S(50) (K(m)) and Hill coefficient differed dependent on substrates used. Midazolam 18-27 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 82-88 14625349-4 2003 Furthermore, a sensitivity analysis of the contribution of CYP3A5 (in addition to CYP3A4) to the metabolism of a "midazolam"-type substrate based on recently published in vitro and clinical data is compared with the results of two in vivo studies that investigated the influence of CYP3A5 genotype on midazolam pharmacokinetics. Midazolam 114-123 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 59-65 14625349-5 2003 The sensitivity analysis predicts an approximately 3-fold lower AUCoral for midazolam for those expressing the highest hepatic and intestinal levels of CYP3A5 (e.g., possessing CYP3A5*1 alleles) compared with those individuals who express insignificant amounts of CYP3A5, assuming CYP3A4 levels are the same in both groups and that CYP3A5 levels do not exceed those of CYP3A4 in CYP3A5*1 homozygotes. Midazolam 76-85 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 152-158 14625349-5 2003 The sensitivity analysis predicts an approximately 3-fold lower AUCoral for midazolam for those expressing the highest hepatic and intestinal levels of CYP3A5 (e.g., possessing CYP3A5*1 alleles) compared with those individuals who express insignificant amounts of CYP3A5, assuming CYP3A4 levels are the same in both groups and that CYP3A5 levels do not exceed those of CYP3A4 in CYP3A5*1 homozygotes. Midazolam 76-85 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 177-183 14625349-5 2003 The sensitivity analysis predicts an approximately 3-fold lower AUCoral for midazolam for those expressing the highest hepatic and intestinal levels of CYP3A5 (e.g., possessing CYP3A5*1 alleles) compared with those individuals who express insignificant amounts of CYP3A5, assuming CYP3A4 levels are the same in both groups and that CYP3A5 levels do not exceed those of CYP3A4 in CYP3A5*1 homozygotes. Midazolam 76-85 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 177-183 14625349-5 2003 The sensitivity analysis predicts an approximately 3-fold lower AUCoral for midazolam for those expressing the highest hepatic and intestinal levels of CYP3A5 (e.g., possessing CYP3A5*1 alleles) compared with those individuals who express insignificant amounts of CYP3A5, assuming CYP3A4 levels are the same in both groups and that CYP3A5 levels do not exceed those of CYP3A4 in CYP3A5*1 homozygotes. Midazolam 76-85 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 177-183 14625349-5 2003 The sensitivity analysis predicts an approximately 3-fold lower AUCoral for midazolam for those expressing the highest hepatic and intestinal levels of CYP3A5 (e.g., possessing CYP3A5*1 alleles) compared with those individuals who express insignificant amounts of CYP3A5, assuming CYP3A4 levels are the same in both groups and that CYP3A5 levels do not exceed those of CYP3A4 in CYP3A5*1 homozygotes. Midazolam 76-85 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 177-183 12202670-10 2002 Nine patients of 25 studied were homozygous for the CYP3A5*3 genotype, and had lower mean clearance of midazolam but not docetaxel. Midazolam 103-112 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 52-58 12433824-7 2002 We excluded other genotypes of CYP3A5 to study the significance of CYP3A5*3 in midazolam pharmacokinetics. Midazolam 79-88 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 67-73 12814972-3 2003 Recombinant CYP3A4 and CYP3A5 (rCYP3A4 and rCYP3A5) both produced 1-OH and 4-OH metabolites from midazolam and triazolam, 6 beta-hydroxytestosterone from testosterone, and oxidized nifedipine from nifedipine. Midazolam 97-106 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29 12814972-10 2003 Thus, CYP3A4 and CYP3A5 both contribute to midazolam, triazolam, testosterone, and nifedipine biotransformation in HLMs, with CYP3A5 being metabolically less active than CYP3A4 in general. Midazolam 43-52 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 17-23 12406645-18 2002 Functionally, microsomes from a CYP3A5*3/*3 liver contain very low CYP3A5 protein and display on average reduced catalytic activity towards midazolam. Midazolam 140-149 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 32-38 10898111-4 2000 In this study, we used midazolam to characterize CYP3A5 phenotype in a panel of liver samples. Midazolam 23-32 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 49-55 12065767-0 2002 Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Midazolam 78-87 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 28-34 12065767-5 2002 Overall, CYP3A5 protein content accounted for 31% of the variability in hepatic midazolam hydroxylation activity. Midazolam 80-89 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 9-15 8043020-5 1994 Midazolam, a prototypic substrate for CYP3A4 and CYP3A5, competitively inhibited dextromethorphan N-demethylation by two human liver microsomal samples with Ki values of 46 +/- 10 and 63 +/- 8 microM. Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 49-55 7826796-4 1994 Whereas cytochrome P450 3A3 metabolized midazolam to the same extent as cytochrome P450 3A4, cytochrome P450 3A5 increased its metabolism by a factor of 2.7. Midazolam 40-49 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 93-112 8185679-10 1994 In conclusion, CYP3A4, CYP3A5, and fetal microsomes containing CYP3A7 catalyze 1"- and 4-hydroxylation of midazolam with the ratio of these metabolites indicative of the CYP3A form. Midazolam 106-115 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29 30501535-7 2020 In vivo CYP3A4 and CYP3A5 expression was evaluated through the metabolism of their substrate midazolam (MID), and detected via ultra-performance liquid chromatography-mass spectrometry. Midazolam 93-102 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 19-25 35202484-2 2022 Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Midazolam 202-211 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 30981185-9 2019 In the inhibition assay, midazolam was used as the probe substrate on genotyped human liver microsomes (CYP3A5 null), and the production of its 1"-substituted metabolite when co-cultured with extract treatments was monitored. Midazolam 25-34 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 104-110 31356678-3 2020 The observed CYP3A5 genetic effect on MDZ systemic and oral clearance was successfully replicated by a mechanistic framework incorporating the proteomics-informed CYP3A abundance and optimized small intestinal CYP3A4 abundance based on MDZ intestinal availability (FG ) of 0.44. Midazolam 38-41 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 13-19 25287072-3 2015 In CYP3A5 non-expressers, the presence of one CYP3A4*22T-allele was associated with a 31.7-33.6% reduction in MDZ apparent oral clearance, reflecting reduced in vivo CYP3A4 activity. Midazolam 110-113 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 3-9 30517006-4 2019 Compared with TST, MDZ was found to correlate better with the content of CYP3A4/5 (no correlation vs 0.431) and CYP3A5 (no correlation vs 0.447), and huge variations in enzyme content existed among different genotypes, which explained the lower degree of correlation at the microsomal level. Midazolam 19-22 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 112-118 29719052-6 2018 Testosterone 6beta-hydroxylation and midazolam 1"-hydroxylation, which are catalysed by both CYP3A4 and CYP3A5 in liver microsomes, were decreased by 25% and 45%, respectively, in the presence of 0.1 mg/ml SO-SWCNT. Midazolam 37-46 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 104-110 28986606-1 2018 OBJECTIVE: The purpose of this study was to investigate the influence of breviscapine on the pharmacokinetics of concomitantly administered midazolam (MID) and its associations with and effects on genetic polymorphism of the gene encoding cytochrome P450 3A5 (CYP3A5) in healthy volunteers. Midazolam 140-149 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 239-258 28986606-1 2018 OBJECTIVE: The purpose of this study was to investigate the influence of breviscapine on the pharmacokinetics of concomitantly administered midazolam (MID) and its associations with and effects on genetic polymorphism of the gene encoding cytochrome P450 3A5 (CYP3A5) in healthy volunteers. Midazolam 140-149 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 260-266 28944677-9 2017 A strong correlation was found between CYP3A4 and CYP3A5 abundance and activity determined using midazolam and testosterone (r > 0.600, p < 0.001). Midazolam 97-106 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 50-56 28533324-0 2017 CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism. Midazolam 117-126 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 36-42 30166405-2 2018 In a cohort of 50 renal transplant recipients who underwent quantification of CYP3A4 activity using the oral midazolam drug probe, we confirmed that CYP3A5 genotype is the single most important determinant of tacrolimus metabolite/parent ratio [CYP3A5 expressors displayed 2.7- and 2-fold higher relative exposure to 13-desmethyltacrolimus (DMT) and 31-DMT, respectively; P < 0.001]. Midazolam 109-118 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 149-155 28344076-5 2017 Notably, the inhibitory intensity of GC towards CYP3A4 was stronger than CYP3A5 when using midazolam and nifedipine as substrates. Midazolam 91-100 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 73-79 27666601-0 2016 Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole. Midazolam 25-34 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 35-41 27511886-0 2016 Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6beta-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. Midazolam 91-100 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 20-26 27511886-3 2016 METHODS: Single oral 15 mg doses of midazolam were given to 20 healthy male Chinese subjects who were genotyped for the CYP3A5*3 and CYP3A4*1G polymorphisms. Midazolam 36-45 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 120-126 26921388-7 2016 1"-Fluoromidazolam was metabolized at the same rate as midazolam by CYP3A4 but was more stable in CYP3A5 incubations. Midazolam 9-18 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 98-104 25590378-9 2015 CYP3A5 activity was assessed by differential midazolam (MDZ) hydroxylation and P-gp (ABCB1 product) activity by a calcein efflux assay. Midazolam 45-54 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 25590378-9 2015 CYP3A5 activity was assessed by differential midazolam (MDZ) hydroxylation and P-gp (ABCB1 product) activity by a calcein efflux assay. Midazolam 56-59 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 24737844-5 2014 For specific reactions in HLMs from *1/*1 donors, CYP3A5 contributes 55% and 44% to midazolam 1"- and 4-hydroxylation, 16% to testosterone 6beta-hydroxylation, 56% and 19% to alprazolam 1"- and 4-hydroxylation, 10% to tamoxifen N-demethylation, and 58% to atazanavir p-hydroxylation. Midazolam 84-93 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 50-56 24214410-0 2014 CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients. Midazolam 31-40 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 24214410-7 2014 The CYP3A5*3 and total bilirubin level significantly influenced MDZ clearance. Midazolam 64-67 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 4-10 24214410-11 2014 Our data indicate that CYP3A5*3, total bilirubin, bodyweight, and creatinine clearance are important predictors of MDZ and metabolite pharmacokinetics. Midazolam 115-118 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29 24696691-4 2014 Midazolam is hydroxylated by CYP3A4 and CYP3A5; the activities of these enzymes surge in the liver in the first weeks of life and thus the metabolic rate of midazolam is lower in neonates than in adults. Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 40-46 24696691-4 2014 Midazolam is hydroxylated by CYP3A4 and CYP3A5; the activities of these enzymes surge in the liver in the first weeks of life and thus the metabolic rate of midazolam is lower in neonates than in adults. Midazolam 157-166 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 40-46 23324807-4 2013 Whereas midazolam is metabolized by both CYP3A4 and CYP3A5, erythromycin is exclusively oxidized by CYP3A4. Midazolam 8-17 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 52-58 24024898-0 2013 Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. Midazolam 47-56 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 10-16 24024898-1 2013 BACKGROUND & AIM: In vitro studies have identified both midazolam and tacrolimus as dual CYP3A4 and CYP3A5 substrates. Midazolam 60-69 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 104-110 23324807-7 2013 RESULTS: In patients expressing CYP3A5, POR*28 carriers showed 45% lower midazolam metabolic ratios compared with POR*1/*1 patients (P<0.001). Midazolam 73-82 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 32-38 23324807-8 2013 This is in line with a lower CYP3A5 activity toward midazolam for POR*28 carriers. Midazolam 52-61 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 21266595-5 2011 Midazolam hydroxylation was also inhibited in human liver microsomes harboring the CYP3A5*3/*3 genotype (poor CYP3A5 expressor). Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 83-89 21266595-3 2011 The effects of sorafenib and sunitinib on midazolam 1"-hydroxylation catalyzed by human CYP3A4 or CYP3A5 were investigated. Midazolam 42-51 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 98-104 22673786-6 2012 Midazolam is primarily metabolized by the CYP3A4/CYP3A5 enzymes. Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 49-55 22511346-5 2012 However, similar results were not obtained when midazolam was used as the probe substrate, suggesting that inactivation of CYP3A5 by lapatinib is site-specific. Midazolam 48-57 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 123-129 21266595-5 2011 Midazolam hydroxylation was also inhibited in human liver microsomes harboring the CYP3A5*3/*3 genotype (poor CYP3A5 expressor). Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 110-116 21266595-6 2011 In contrast, midazolam 1"-hydroxylation catalyzed by recombinant CYP3A5 was enhanced by the coexistence of sorafenib or sunitinib in a concentration-dependent manner, with saturation occurring at approximately 10 muM. Midazolam 13-22 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 65-71 21266595-7 2011 Midazolam hydroxylation was also enhanced in human liver microsomal samples harboring the CYP3A5*1/*1 genotype (extensive CYP3A5 expressor). Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 90-96 21266595-7 2011 Midazolam hydroxylation was also enhanced in human liver microsomal samples harboring the CYP3A5*1/*1 genotype (extensive CYP3A5 expressor). Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 122-128 21266595-10 2011 Docking studies with a CYP3A5 homology model based on the structure of CYP3A4 revealed that midazolam closely docked to the heme of CYP3A5 compared with sorafenib or sunitinib, suggesting that these anticancer drugs act as enhancers, not as substrates. Midazolam 92-101 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 23-29 21266595-10 2011 Docking studies with a CYP3A5 homology model based on the structure of CYP3A4 revealed that midazolam closely docked to the heme of CYP3A5 compared with sorafenib or sunitinib, suggesting that these anticancer drugs act as enhancers, not as substrates. Midazolam 92-101 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 132-138 21266595-11 2011 Our results thus showed that sorafenib and sunitinib activated midazolam 1"-hydroxylation by CYP3A5 but inhibited that by CYP3A4. Midazolam 63-72 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 93-99 20954901-0 2011 CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity. Midazolam 30-39 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 0-6 20954901-3 2011 The aim of this study was to explore the effect of varying activities of the electron donor NADPH-cytochrome P450 reductase (CPR) on CYP3A5-mediated metabolism of MDZ. Midazolam 163-166 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 133-139 19506580-2 2009 Midazolam (MDZ) is a substrate for both CYP3A4 and CYP3A5. Midazolam 0-9 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 51-57 21281268-6 2010 Ketoconazole more potently inhibited CYP3A4 than CYP3A5 for both domperidone and midazolam. Midazolam 81-90 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 49-55 20814160-7 2010 mfCYP3A5 and CYP3A5 catalyzed midazolam 1"-hydroxylation at a low substrate concentration more efficiently than the corresponding CYP3A4. Midazolam 30-39 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 2-8 19506580-2 2009 Midazolam (MDZ) is a substrate for both CYP3A4 and CYP3A5. Midazolam 11-14 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 51-57 17954524-3 2008 Fluconazole was a slightly more potent inhibitor of CYP3A activity in CYP3A5-HLM than in CYP3A5+ HLM with midazolam (K(i) of 15 and 25 microM, respectively) but not with erythromycin (IC(50) of 70 and 54 microM, respectively). Midazolam 106-115 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 89-95 18001057-2 2007 The corresponding residue in CYP3A5 is S239, and when the potential for TDI in P450 3A5 was investigated, only reversible inhibition was observed against midazolam and testosterone, with median inhibitory concentration (IC50) values of 2.4 and 2.9 microM, respectively. Midazolam 154-163 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 29-35 17786417-0 2007 Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation. Midazolam 33-42 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 14-20 17554244-0 2007 Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Midazolam 121-130 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 13-19 18948377-8 2009 Enhanced midazolam hydroxylation by thalidomide was also seen in liver microsomal samples harboring the CYP3A5*1 allele. Midazolam 9-18 cytochrome P450 family 3 subfamily A member 5 Homo sapiens 104-110